China Ophthalmology Focus eyes Asia market

Lee’s ophthalmology spin-off hopes its focus could catch the eye of investors

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with its portfolio of novel and generic ophthalmology products.

The company spun out of Lee’s with a $50 million series A round and 21 programs in development, including nine innovative compounds and 12 generics that span dry eye diseases, glaucoma, wet age-related macular degeneration

Read the full 774 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers